- Home
- IBO vs ALLK Comparison
IBO vs ALLK Comparison
Compare IBO & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- ALLK
- Stock Information
- Founded
- IBO 2018
- ALLK 2012
- Country
- IBO United States
- ALLK United States
- Employees
- IBO N/A
- ALLK N/A
- Industry
- IBO
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- ALLK Health Care
- Exchange
- IBO NYSE
- ALLK Nasdaq
- Market Cap
- IBO 22.1M
- ALLK 23.0M
- IPO Year
- IBO 2024
- ALLK 2018
- Fundamental
- Price
- IBO $0.43
- ALLK $0.33
- Analyst Decision
- IBO
- ALLK Hold
- Analyst Count
- IBO 0
- ALLK 3
- Target Price
- IBO N/A
- ALLK $2.00
- AVG Volume (30 Days)
- IBO 9.7M
- ALLK 2.2M
- Earning Date
- IBO 05-23-2025
- ALLK 05-08-2025
- Dividend Yield
- IBO N/A
- ALLK N/A
- EPS Growth
- IBO N/A
- ALLK N/A
- EPS
- IBO N/A
- ALLK N/A
- Revenue
- IBO N/A
- ALLK N/A
- Revenue This Year
- IBO N/A
- ALLK N/A
- Revenue Next Year
- IBO N/A
- ALLK N/A
- P/E Ratio
- IBO N/A
- ALLK N/A
- Revenue Growth
- IBO N/A
- ALLK N/A
- 52 Week Low
- IBO $0.37
- ALLK $0.22
- 52 Week High
- IBO $6.17
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- ALLK 60.40
- Support Level
- IBO N/A
- ALLK $0.31
- Resistance Level
- IBO N/A
- ALLK $0.33
- Average True Range (ATR)
- IBO 0.00
- ALLK 0.00
- MACD
- IBO 0.00
- ALLK 0.00
- Stochastic Oscillator
- IBO 0.00
- ALLK 78.50
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.